CD20-Positive Acute Lymphoblastic Leukemia: Obinutuzumab vs. Rituximab

We are comparing two treatments, obinutuzumab and rituximab, for adults with newly diagnosed CD20-positive acute lymphoblastic leukemia. The goal is to see which treatment helps more patients achieve complete remission safely.

>2 years11-15 visitsEfficacy phase (II)No PlaceboStandard MedicinesInjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Obinutuzumab
Obinutuzumab is a lab-made antibody that targets and helps eliminate B cells to treat certain blood cancers like chronic lymphocytic and follicular lymphoma.
Rituximab
Rituximab is a substance that targets and reduces B cells, a type of white blood cell, to treat some blood cancers and autoimmune conditions.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Uniwersytecki Szpital Kliniczny W Bialymstoku
Klinika Hematologii, Chorób Wewnętrznych i Angiologii z Pododdziałem Transplantacji Komórek Krwiotw.
Białystok, Poland
Szpital Specjalistyczny Im. Ludwika Rydygiera W Krakowie Sp. z o.o.
Oddział Hematologii i Chorób Wewnętrznych z Pododdziałem Dziennym
Bieńczyce, Poland
Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza
Oddział Hematologii Onkologicznej
Brzozów, Poland
Sponsor: Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.